Expression of FOXC1, a forkhead box transcription factor, correlates with the human basal-like breast cancer (BLBC) subtype, and functional analyses have revealed its importance for in vitro invasiveness of BLBC cells. Women diagnosed with this breast tumor subtype have a poorer outcome because of the lack of targeted therapies; thus, continued investigation of factors driving these tumors is critical to uncover novel therapeutic targets. Several processes that dictate normal mammary morphogenesis parallel cancer progression, and enforced expression of FOXC1 can induce a progenitor state in more-differentiated mammary epithelial cells. Consequently, evaluating how FOXC1 functions in the normal gland is critical to further understand BLBC biology. Although FOXC1 is well known to control normal development of a number of tissues, its role in the mammary gland has not yet been investigated. Herein, we describe FOXC1 expression patterning in the normal breast, where it is localized to the basal/myoepithelium, suggesting that FOXC1 would be required for normal development. However, mammary glands lacking Foxc1 have no overt defect in ductal outgrowth, alveologenesis, or lineage specification. Of significant interest, we found that expression of FOXC1 is enriched in the normal luminal progenitor population, which is the postulated cell of origin of BLBC. These results indicate that FOXC1 is unnecessary for mammary morphogenesis and that its role in BLBC likely involves processes that are unrelated to cell lineage specification.
INTRODUCTION
FOXC1 (Mf1, FKHL7, FREAC3) is a member of the forkhead box (FOX) family of transcription factors, and, similar to other FOX family members, its expression is crucial for the normal development of multiple organs [1] [2] [3] [4] [5] [6] . Mice null for FOXC1 die perinatally because of hydrocephalus, but also present with severe skeletal and eye abnormalities [1] . The role for FOXC1 in the development of the meninges has been further evaluated through generation of a Foxc1 hypomorphic mutant allele (hith) that, although viable through adulthood, has dysmorphic skull formation and other cortical pathologies [7] . In humans, autosomal dominant mutations within FOXC1 are responsible for Axenfeld-Rieger syndrome [8] , a disorder characterized by craniofacial and anterior ocular developmental defects. More recently, aberrant expression of FOXC1 has been implicated in metastasis of hepatic, endometrial, and breast tumors [9] [10] [11] .
In breast cancer specifically, FOXC1 is differentially expressed in tumors designated as basal-like [11] [12] [13] , and we have shown that FOXC1 mediates basal-like breast cancer (BLBC) cell invasion [11] . Tumors of the BLBC subtype are intrinsically more aggressive than other breast cancer subtypes [14] , and are often characterized by the absence of estrogen receptor a (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) (i.e., ''triplenegative''), although only gene expression profiling can truly define a tumor as basal-like [15] [16] [17] . Because of the lack of known molecular targets, patients harboring tumors of this subtype have a poorer prognosis, making continued evaluation of factors involved in BLBC biology essential for identifying pathways with therapeutic potential.
Several activities involved in normal mammary gland development parallel the processes of tumorigenesis (e.g. proliferation, migration, evasion of apoptosis, angiogenesis); thus, it is not surprising that many of the key players in tumorigenesis have indispensable roles in morphogenesis of the normal gland [18, 19] . Identifying how these factors function normally has provided great insight into their aberrant function in cancer, including control of the BLBC phenotype. Most notably, loss of BRCA1 inhibits pregnancy-induced mammary gland development and is involved in mammary stem cell (MaSC) maintenance [14, 20, 21] . In vitro overexpression of FOXC1 induces the acquisition of progenitor cell properties in nontransformed human mammary epithelial cells, suggesting that FOXC1 may control cell fate determination during normal mammary gland morphogenesis [22] .
However, although FOXC1 is a well known BLBC factor and is crucial for the normal development of several organ systems [1] [2] [3] [4] [5] [6] , its role during mammary gland development is currently unknown.
Herein, we describe the first characterization of the expression pattern of FOXC1 in the normal breast. FOXC1 is expressed in the normal basal/myoepithelium of the terminal ductal lobular unit (TDLU), is maintained in ductal carcinoma in situ (DCIS), and is present in a subset of triple-negative invasive ductal carcinomas (IDCs). Expression in the normal duct further supported the hypothesis that FOXC1 would be required during normal mammary gland development. We evaluated the impact of FOXC1 on mammary gland morphogenesis using mice with a germ-line disruption of Foxc1. Importantly, loss of FOXC1 does not affect mammary ductal outgrowth, alveologenesis, or lineage commitment. Further evaluation of Foxc1 expression in fluorescence-activated cellsorted (FACS) mouse mammary cells revealed its expression is highest in the luminal progenitor cell population, which is thought to be the cell of origin for BLBC tumors [23, 24] . These data support continued analyses of FOXC1 in stem/ progenitor cell maintenance and BLBC tumorigenesis, but indicate that FOXC1 is unnecessary for cell fate determination in the normal gland.
MATERIALS AND METHODS

Animal Breeding
All animal procedures were approved by the Case Western Reserve University Institutional Animal Care and Use Committee. Mice were maintained in microisolator units on a 12L:12D cycle with food and water given ad libitum. Foxc1 þ/À mice were generated as described [1] . Heterozygotes were bred into the C57BL/6 strain at least six generations. Foxc1 þ/À male and female mice were intercrossed to generate Foxc1
, and Foxc1 À/À progeny. Foxc1 À/À embryos were distinguished by gross morphology and confirmed by PCR using primers as described [1] . Foxc1 þ/þ and Foxc1 þ/À mice were also distinguished by PCR. SIZEMORE ET AL.
Mammary Anlagen Transplantation
Transplantation of mammary anlagen into recipient mice has been described [25, 26] . Foxc1 þ/þ or Foxc1 þ/À anlage was inserted into one cleared fat pad, and Foxc1 À/À anlage was inserted into the contralateral cleared fat pad of the same mouse. Recipient mice were aged 5 wk, transplanted glands collected, and whole mounts examined. A second cohort of recipient mice was aged 4-5 wk following transplantation. These mice were then ovariectomized, and after 1 wk were injected subcutaneously with 17b-estradiol (1 lg/day) plus progesterone (0.5-1 mg/day) for 14-18 days, at which time transplanted glands were collected for whole-mount analyses. A third cohort of mice was aged and mated with C57BL/6 males, and transplanted glands were collected at 17.5 days postcoitum (dpc).
Mammary Gland Whole Mounts and b-Galactosidase Detection
For whole-mount analysis, glands were fixed in Khale fixative for at least 4 h, washed in 70% ethanol, gradually rehydrated to 100% water, stained with carmine alum, dehydrated, cleared in xylenes, and mounted as previously described [25, 26] . To detect b-galactosidase activity, embryos were fixed at room temperature for 1 h in 0.1 M sodium phosphate (pH 8.8) plus 2% paraformaldehyde, 0.2% glutaraldehyde, 5 mM EGTA (pH 7.3), 2 mM MgCl 2 , 0.02% NP40, and 0.01% sodium deoxycholate. The fixed embryos were then washed (0.1 M sodium phosphate [pH 8] plus 2 mM MgCl 2 , 0.02% NP40, and 0.01% sodium deoxycholate) and stained (wash buffer plus 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, and 50 mg/ml X-gal) for 3 h at 378C, followed by overnight incubation at room temperature. Embryos were then postfixed in 4% paraformaldehyde and stored in 13 PBS at 48C.
Immunohistochemistry and Immunofluorescence
Deidentified human breast tissue sections were obtained through the Department of Pathology archives at University Hospitals Case Medical Center, where they were previously processed and evaluated for ER, PR, and HER2 expression (IRB protocol CASE 1108). Seventy-three samples were evaluated, representing the following receptor-defined subtypes: ERþ/PRþ/ HER2À (n ¼ 18), HER2þ (n ¼ 37), and ERÀ/PRÀ/HER2À (n ¼ 18). Nuclear FOXC1 staining was quantified by signal intensity on a 3þ scale, and for statistical analyses samples were dichotomized into low (0) and high (1-3þ) groups. Statistical comparisons between FOXC1 positivity and breast cancer subtypes were made by chi-square analyses.
Mouse mammary glands were fixed in 4% paraformaldehyde for 4 h, transferred to 13 PBS, paraffin embedded, and sectioned (5 lm). Sections were rehydrated, and antigen retrieval was performed using 10 mM sodium citrate (pH ¼ 6) in a pressure cooker (1258C for 10 min; 908C for 2 min). For immunohistochemistry (IHC), sections were blocked with peroxidase blocking reagent (Dako) and incubated with primary antibody overnight at 48C (FOXC1, #7415, Cell Signaling; FOXC2, #ab5060, Abcam; p63, #LS-C95504, Lifespan Biosciences; ER, #sc-542, Santa Cruz; cytokeratin 8 [CK8] [TROMA-1], Developmental Studies Hybridoma Bank, University of Iowa). Secondary detection of FOXC1, FOXC2, and ER was performed using the appropriate Vectastain Elite ABC Kit (Vector Laboratories), of p63 using the Vector M.O.M. Immunodetection kit (Vector Laboratories), and of CK8 using the EnVisionþSystem-HRP for mouse antibodies (Dako), each according to manufacturer's recommendations. Secondary conjugates were detected using 3,3 0 -diaminobenzidine (Dako). Sections were counterstained with Gill #3 hematoxylin (Fisher), dehydrated, and mounted. Hematoxylin-eosin (H&E) staining was performed by the Case Western Reserve University Tissue Procurement and Histology Core Facility. For immunofluorescence, sections were rehydrated and antigen retrieval performed as described above. Sections were then blocked in 5% bovine serum albumin (BSA)-0.5% Tween-20-13 PBS and incubated overnight at 48C with antibodies targeting FOXC1 and/or CK8 in blocking buffer. After washing, Alexa Fluor 488 goat anti-rabbit SFX (A31628; Molecular Probes) and Texas Red-X goat anti-rat (T6392; Molecular Probes) were used to detect FOXC1 and CK8, respectively. The sections were counterstained with 4 0 ,6-diamidino-2-phenylindole and mounted.
Immunoblots
Embryos were homogenized on ice in lysis buffer (50 mM Tris-HCl, pH 7.4; 100 mM NaCl; 1 mM EDTA; 1 mM EGTA; 1 mM NaF; 0.1% SDS; 0.5% sodium deoxycholate; 1% Triton-X-100; 10% glycerol; 2 mM sodium orthovanadate; protease inhibitor cocktail; Sigma), and protein levels quantified (Bradford Assay; Biorad). Protein lysate was resolved using SDS-PAGE and transferred to polyvinylidene fluoride membrane (BioRad). Blots were blocked (5% milk 13 Tris buffered saline with Tween-20 [TSBT]) and incubated overnight at 48C with FOXC1 antibody (#7415; Cell Signaling) in 5% BSA-13 TBST. Blots were incubated with a horseradish peroxidase-conjugated secondary antibody (Santa Cruz) diluted in 5% milk-13 TBST and developed using ECL reagent (Pierce).
Mammary Cell Preparation, FACS, and Quantitative RealTime PCR
The isolation and purification of the MaSC (CD24
, and mature luminal (CD24 þ /CD29 lo / CD61 À ) populations was performed at the Walter and Eliza Hall Institute of Medical Research as has been described [26] [27] [28] . Total RNA was treated with DNAse I (DNA-free; Ambion) and cDNA produced using SuperScript II Reverse Transcriptase (Invitrogen). Complementary DNAs for Trp63, Kit, Esr1, Foxc1, and Gapdh were preamplified for 14 cycles prior to quantification by real-time PCR performed using Applied Biosystems TaqMan Gene Expression Assays (assay IDs: Trp63, Mm00495788_m1; Kit, 
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Mm00445212_m1; Esr1, Mm01191130_m1; Foxc1, Mm01962704_s1; Gapdh, 4352932E). Statistical significance between sorted populations was determined by Student t-test assuming a two-tailed distribution and equal variance.
RESULTS
FOXC1 Is Expressed in the Normal Mammary Basal/ Myoepithelium
FOXC1 has been reported to be prognostic and functionally relevant in BLBC [11] [12] [13] . However, the analysis of FOXC1 protein in breast cancer patient samples to date has been limited to a population enrolled at a single institution and was completed with a different antibody than we report herein [12, 13] . To determine if FOXC1 expression is associated with triple-negative breast cancers in an independent patient cohort, we performed immunohistochemistry on 73 human breast tumor sections representing the luminal (ERþ/PRþ/HER2À), HER2þ (ERþ/PRþ/HER2þ and ERÀ/PRÀ/HER2þ) and triple-negative (ERÀ/PRÀ/HER2À) subtypes (Fig. 1A) . Nuclear FOXC1 expression was quantified and FOXC1 positivity was significantly (P , 0.03) correlated with the triple-negative patient cohort relative to the luminal and HER2 subtypes (Fig.  1B) . Notably, even in the triple-negative population, FOXC1 expression occurred in a minority of tumors likely representing the BLBC subset, as has been demonstrated previously [12, 13] . Through this analysis we also observed strong expression in basal/myoepithelial cells of normal TDLUs (Fig. 1C) , which has not previously been reported. This expression pattern was maintained in DCIS, but was absent in the majority of IDCs, as quantified in Figure 1B . The restriction of FOXC1 expression in the basal/myoepithelium was similarly observed in the normal mouse mammary gland, where immunofluorescence for FOXC1 in combination with a well-described luminal epithelial marker, cytokeratin 8 (CK8), showed essentially no overlap in signal (Fig. 2) .
FOXC1 Is Not Required for Mammary Gland Development
FOXC1 localization in the normal basal/myoepithelium suggests that this transcription factor may function during mammary gland development. To evaluate this postulate, we utilized a germ-line Foxc1 knockout mouse that has previously been described [1] . Mammary gland development begins at Embryonic Day 10 (e10) with rudimentary anlagen observable after e11 [29] . Foxc1-null embryos depicted normal mammary anlagen formation at e17.5 (Fig. 3) , indicating that FOXC1 is not required during the embryonic stages of mammary morphogenesis. Because of the perinatal lethality of these mice, we used an orthotopic transplantation approach to evaluate mammary morphogenesis after birth. Anlagen were dissected from control and Foxc1-null embryos and transplanted into the cleared fat pads of wild-type syngeneic C57BL/6 recipients. Anlagen from both Foxc1 þ/þ and Foxc1 þ/À embryos were used as controls because we observed no consistent differences in mammary ductal elongation or side branching in pubertal heterozygous mice (data not shown). Importantly, dissection of control and Foxc1 À/À embryos for the orthotopic transplantation experiments corroborated the results depicted in Figure 3 in a larger cohort of animals, with all Foxc1 À/À having discernible anlagen (control ¼ 9; Foxc1 À/À ¼ 13). Resulting outgrowths were evaluated in virgin hosts after 5 wk. This analysis revealed that Foxc1-null anlagen are capable of forming mammary ductal outgrowths at the same frequency as control mice (Fig. 4A) . Because the factors regulating ductal elongation are distinct from those involved in alveologenesis [30] , we also performed orthotopic transplants to evaluate alveolar differentiation induced either by exogenous treatment with 17b-estradiol and progesterone (Fig. 4B) or through pregnancy (Fig. 4C) . The absence of FOXC1 did not impair alveologenesis in either model. Combined, these data demonstrate that FOXC1 expression is not necessary for mammary ductal elongation or pregnancy-induced alveologenesis.
Although Foxc1-null glands do not have any observable overt morphological defects, we further investigated whether epithelial lineage specification was disrupted by histological evaluation of p63, ER, and CK8 (Fig. 5) . Expression of p63 marks cells of the basal/myoepithelial lineage including, but not limited to, the MaSC compartment. ER is expressed in the 
majority of mature luminal cells, whereas CK8 shows widespread expression in the luminal epithelium. Foxc1-null glands exhibited no alterations in the expression pattern of p63, ER, and CK8, indicating that FOXC1 is not necessary for lineage specification of the mammary epithelium (Fig. 5A ). More specifically, quantification of nuclear p63 in the myoepithelium (control ¼ 74% 6 7%; À/À ¼ range 68%-72%) and ER in the luminal epithelium (control ¼ 44% 6 7%; À/À ¼ range 40%-46%) showed no difference in the percentage of positive cells in the Foxc1-null glands. We also evaluated the expression of these three lineage markers in control and Foxc1-null transplanted glands harvested from mice treated exogenously with 17b-estradiol and progesterone. As seen in the virgin cohort, there was no difference in the expression pattern of p63, ER, and CK8 in the absence of FOXC1 (Fig. 5B) . Because of the established down-regulation of ER by estrogens, ER expression was expectedly low in the 17b-estradiol and progesterone-treated glands [31, 32] .
FOXC2 Does Not Compensate for Loss of FOXC1
Observing that FOXC1 is not necessary for mammary morphogenesis or lineage specification led us to evaluate whether the closely related forkhead factor, FOXC2, may act in a compensatory manner. FOXC2 is similarly associated with BLBC tumors [33] , and could also be predicted to have a developmental role in the mammary gland. Furthermore, FOXC2 compensates for loss of FOXC1 in other tissues [4] . Immunohistochemical analysis revealed that FOXC2 was undetectable in the normal mouse mammary gland, and, more importantly, was not up-regulated in the absence of FOXC1 (Fig. 6A) . This absence of FOXC2 in the normal gland was consistent with previous findings in normal human breast tissue [33] . Of note, upon immunohistochemical evaluation of FOXC1 in the Foxc1-null tissues, we detected positive staining indistinguishable from that of control mice (Fig. 6A) . To confirm antibody specificity, we subsequently immunostained serial sections from the 17b-estradiol and progesterone transplantation cohort with FOXC1 and a no-primary-antibody control (Fig. 6B) . This negative control exhibited minimal background staining (Fig. 6B) . The maintenance of FOXC1 IHC signal in the knockout glands can readily be explained by the fact that the anti-FOXC1 antibody was generated against a peptide surrounding tyrosine 64, which was still expressed in the knockout mice. To affirm that the antibody detected both the truncated and the wild-type allele, we performed Western blot analyses of whole embryo lysates generated from wildtype, heterozygous null, and knockout animals. The disrupted knockout protein had a predicted molecular mass of 126 kDa because of fusion of LacZ with the first 89 amino acids of FOXC1, whereas the wild-type protein was 75 kDa. This analysis confirmed that the truncated protein was expressed and can be readily detected with this antibody (Fig. 6C) . Of note, although the knockout FOXC1 protein is immunodetectable, it is functionally inactive because of the absence of DNAbinding activity [1] . Thus, this antibody should provide a useful tool for FOXC1 IHC in diagnostic and prognostic assays.
FOXC1 Is Expressed in the Normal Luminal Progenitor Population
Although mammary glands lacking FOXC1 do not exhibit overt defects in ductal outgrowth, alveologenesis, or lineage specification, loss of FOXC1 could impact the maintenance of 
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the stem or progenitor cell population, which would not be detectable in the experiments just described. To further discern Foxc1 expression patterning in the mammary epithelial cell hierarchy, we quantified expression in FACS MaSCs, luminal progenitors, and mature luminal cells (Fig. 7A) . Foxc1 expression was significantly enriched in the luminal progenitor population versus the MaSC and mature luminal populations (P , 0.05). The purity of each population was also confirmed by the presence and absence of population-specific markers as described previously [34] : Trp63 served as a MaSC-specific marker, whereas Kit and Esr1 were markers of the luminal progenitor and mature luminal populations, respectively (Fig.  7B) . In total, these data confirmed that FOXC1 is present in the normal mammary gland, specifically in the luminal progenitor population, which is the lineage proposed to be the cell of origin of BLBCs [23, 24] . À/À mammary glands harvested from (A) virgin orthotopic transplant recipients at 5 wk posttransplant (control, n ¼ 4; À/À, n ¼ 2) and (B) recipients that were aged 5 wk posttransplant, ovariectomized, and treated with 17b-estradiol (1 lg/day) plus progesterone (0.5-1 mg/day) (control, n ¼ 3; À/À, n ¼ 3). IHC (brown) is counterstained with hematoxylin. Scale bars ¼ 20 lm.
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DISCUSSION
Herein, we report that mammary gland ductal outgrowth, lineage specification, and alveologenesis do not require expression of FOXC1. This is an important finding given the known role for FOXC1 in BLBC [11] [12] [13] , its ability to induce progenitor cell states in vitro [22] , and its expression pattern in the normal breast as described in this study. A potential explanation for the absence of phenotype upon Foxc1 loss is transcriptional compensation by FOXC2, as has been observed previously in other tissues [4] ; however, we did not observe FOXC2 expression in either normal or Foxc1-null mammary ) and Foxc1 À/À mammary glands harvested from orthotopic transplant recipients that were aged 5 wk posttransplant, ovariectomized, and treated with 17b-estradiol (1 lg/day) plus progesterone (0.5-1 mg/day) (control, n ¼ 3; À/À, n ¼ 3). IHC (brown) is counterstained with hematoxylin. Inset ¼ no primary antibody control. Scale bars
, and Foxc1 À/À embryos collected at 15-16 dpc. The protein from the wild-type allele is 75 kDa, and the knockout allele produces a 126-kDa protein because of the fusion with the lacZ cassette (*, nonspecific bands).
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epithelium. These data suggest that FOXC2 does not compensate for loss of FOXC1 in the mammary gland. However, although we confirmed FOXC2 does not become detectable by IHC in Foxc1-null mammary glands, we cannot rule out the possibility that there are subtle but physiologically relevant changes in expression that are not discernible by this methodology. It is also conceivable that other FOX family members compensate for FOXC1. The forkhead/winged helix domain is highly homologous within the family [35] , and other FOX factors are involved in mammary development [26, 36] .
Another possible explanation for the unaltered phenotype in Foxc1-null mammary glands is that FOXC1 mediates an aspect of mammary morphogenesis not observable with the orthotopic transplantation model, such as puberty-induced ductal lengthening or stem/progenitor cell maintenance. This prospect is exemplified by the mammary phenotype observed in the absence of the Wnt receptor Lrp5, another BLBC factor [37] . Mice lacking Lrp5 are viable [38] ; thus, unlike in the Foxc1-null mice, endogenous ductal lengthening can be evaluated. Loss of Lrp5 causes a developmental delay in ductal elongation, but, as seen with Foxc1-null glands, the glands are histologically normal [39] . Continued investigation has revealed that Lrp5-null mammary glands have reduced regenerative capacity because of a reduction in stem cell number [39, 40] . Importantly, our analyses did reveal highest FOXC1 expression in the mammary luminal progenitor population. These observations suggest FOXC1 may similarly function in mammary stem/progenitor cell maintenance, but given the requirement for anlagen transplantation to rescue the Foxc1 knockout glands, the experiments required to test this hypothesis (e.g., FACS, limiting dilution analyses) were beyond the scope of our current investigation. To overcome this limitation, future analyses would be facilitated by utilizing mice with conditional deletion of Foxc1. Floxed Foxc1 mice have recently been described [41] .
The luminal progenitor cell population is the predicted origin for BLBC [23, 24] ; hence, the presence of FOXC1 in this population further supports its role in this disease. Continued evaluation of FOXC1 function in BLBC phenotypes in both human and murine model systems is warranted, but, based on our findings, should now veer away from questions pertaining to lineage specification to focus on stem/progenitor cell maintenance. Generation of mice conditionally lacking FOXC1 in the mammary gland will be useful not only in addressing alterations in progenitor populations, but also in evaluating how loss of FOXC1 affects mammary tumorigenesis. The correlation of FOXC1 overexpression with the BLBC subtype and its ability to dictate the invasiveness of BLBC cell lines [11] [12] [13] suggests that loss of FOXC1 may hinder tumor formation in mouse models recapitulating this disease [42, 43] . Importantly, conditional loss of Foxc1 will circumvent the systemic and potentially confounding developmental defects observed with germ-line disruption that may also impact tumorigenicity. Although deletion of Foxc1 in BLBC model systems should provide insight into its requirement in this disease, it will also be critical to overexpress FOXC1 in the mammary gland to evaluate either if its expression is sufficient to induce BLBC on its own, or if overexpression causes a phenotypic shift in luminal breast cancer model systems [42] towards a more basal-like phenotype.
Beyond evaluating FOXC1 function in the normal mouse mammary gland, we also investigated its expression patterning in human breast tumor sections. We report for the first time that FOXC1 is highly expressed in the basal/myoepithelia of normal TDLUs and DCIS. Nuclear FOXC1 positivity in tumor tissue was also significantly associated with the triple-negative breast cancer subtype, confirming previously reported observations with an independent cohort of patients [12, 13] . Importantly, we used an anti-FOXC1 antibody that varies in epitope recognition from the one cited by Ray and colleagues [13] , and have confirmed the specificity of this antibody through proper detection of wild-type, heterozygous, and knockout Foxc1 alleles in whole-embryo protein lysates. Furthermore, these analyses have discovered that beyond being a marker of the triple-negative/basal-like subtype, the positive FOXC1 staining observed in the normal basal/myoepithelium may provide a previously unrecognized clinical utility in delineating breast cancer progression from DCIS to invasive carcinoma. This possibility will require additional analyses of early-stage tumors using staining for FOXC1 as well as other markers such as p63 and a-smooth muscle actin to determine if FOXC1 staining is more effective for identifying disease progression compared to current approaches.
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